ATG7 and chronic myelogenous leukemia, BCR-ABL1 positive: This revealed that ATG7 knockdown alone inhibited expansion of CML CD34+ cells and combination of either nilotinib or dasatinib with ATG7 knockdown further inhibited cellular expansion (although the effect did not reach statistical significance; Fig. S6B).